Literature DB >> 6450246

Anti-recipient cytotoxic T lymphocyte precursors are present in the spleens of mice with acute graft versus host disease due to minor histocompatibility antigens.

B L Hamilton, M J Bevan, R Parkman.   

Abstract

A model for bone marrow transplantation across minor histocompatibility barriers was developed by using mouse strains that were H-2 identical and mutually non-reactive in MLC. Acute graft-vs-host disease was induced only when donor lymphoid cells were included in the marrow inoculum, in both C57BL/6 recipients of LP cells and BALB/c recipients of B10.D2/nSN cells. GVHD was prevented by treating the lymphoid cells with anti-Thy 1.2 and C before transplantation. Spleen cells from mice with acute GVHD were not directly cytotoxic to recipient strain target cells. However, when spleen cells from mice with GVHD were boosted in vitro to recipient strain stimulator cells they generated a specific anti-recipient cytotoxic response. Spleen cells from mice without GVHD did not generate a cytotoxic response in vitro. The cytotoxic effector cells and their precursors were shown to be T lymphocytes. This model and the in vitro method described may be useful in further studies of the immunobiology of GVHD due to minor histocompatibility antigens and of transplantation tolerance.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6450246

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Recipient B cells are not required for graft-versus-host disease induction.

Authors:  Catherine Matte-Martone; Xiajian Wang; Britt Anderson; Dhanpat Jain; Anthony J Demetris; Jennifer McNiff; Mark J Shlomchik; Warren D Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-23       Impact factor: 5.742

2.  Sex-dependent effects of non-H-2 loci on lethal GVH reaction induced across an H-2 barrier.

Authors:  O Halle-Pannenko; J Y Mary; R Motta
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

Review 3.  Bone marrow transplantation: the genetic and cellular basis of resistance to engraftment and acute graft-versus-host disease.

Authors:  J Ferrara; P Mauch; G Murphy; S J Burakoff
Journal:  Surv Immunol Res       Date:  1985

Review 4.  Preparation for bone marrow transplantation.

Authors:  R Parkman
Journal:  Springer Semin Immunopathol       Date:  1984

5.  Sequential measurement of the murine acute-phase protein serum amyloid P component (SAP) as an indicator of graft-versus-host disease following allogeneic bone marrow transplantation in mice.

Authors:  K F Bayston; R Huby; J Cohen
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

6.  Lymphokine activity production in graft-versus-host reactions across minor histocompatibility antigen barriers.

Authors:  M Hirokawa; H Takatsu; A Ohshima; A Chubachi; K Kudo; H Niitsu; T Takahashi; K Yoshida; A B Miura
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

7.  A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation.

Authors:  K Riesner; M Kalupa; Y Shi; S Elezkurtaj; O Penack
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

8.  Unraveling graft-versus-host disease and graft-versus-leukemia responses using TCR Vβ spectratype analysis in a murine bone marrow transplantation model.

Authors:  Stacey L Fanning; Jenny Zilberberg; Johann Stein; Kristin Vazzana; Stephanie A Berger; Robert Korngold; Thea M Friedman
Journal:  J Immunol       Date:  2012-11-30       Impact factor: 5.422

9.  Analysis of graft-versus-host disease (GVHD) and graft rejection using MHC class I-deficient mice.

Authors:  S Shenoy; K Desch; B Duffy; P Thorson; T Mohanakumar
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

10.  Depletion of asialo-GM1+ cells from the F1 recipient mice prior to irradiation and transfusion of parental spleen cells prevents mortality to acute graft-versus-host disease and induction of anti-host specific cytotoxic T cells.

Authors:  K Varkila
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.